Pancreas-Intestinal Transplantation in Familial Adenomatous Polyposis Patients.
- Author:
Young Moon JANG
1
;
John J FUN
;
K ABU-ELMAG
;
Thomas E STARZL
Author Information
1. Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center.
- Publication Type:Original Article
- Keywords:
Familial adenomatous polyposis;
Pancreas-intestinal transplantation
- MeSH:
Adenomatous Polyposis Coli*;
Adult;
Cost-Benefit Analysis;
Diabetes Complications;
Humans;
Pancreas Transplantation;
Parenteral Nutrition, Total;
Pediatrics;
Quality of Life;
Transplants
- From:Journal of the Korean Surgical Society
2000;58(6):867-871
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Familial adenomatous poliposis is autosomal, predominantly inherited, premalignant disease, which is caused by a mutation in adenomatous poliposis coli gene in chromosome 5q21. Intestinal transplantation is an evolving procedure and has become a lifesaving procedure for pediatrics and adults with intestinal failure who cannot be managed by conventional therapies. Long-term outcome and cost effectiveness continue to improve and will be comparable to those of total parenteral nutrition. The short gut syndrome is the most common indication. Pancreas transplantation, as a solid organ, vascularized graft, has im proved the quality of life for diabetic patients by establishing an insulin-independent, constant normo glycemic state and is a well-established treatment for patients with insulin-dependent diabetes. The bene ficial effect is the maintenance of normoglycemia and possibly the reversal of diabetic complications, such as vasculopathy, neuropathy, and nephropathy. We report a case of pancreas-intestinal transplantation in a familial adenomatous polyposis patient along with a review of the literature.
